Abstract 1586P
Background
Understanding the natural history of patients with GC/GEJ adenocarcinoma treated previously with anti-HER2 regimens is useful for understanding the disease burden and selecting the optimal Tx for this population. This study reports Tx patterns and outcomes of patients with GC/GEJ adenocarcinoma treated previously with anti-HER2-based regimens.
Methods
Adults with advanced/metastatic GC/GEJ adenocarcinoma who received first-line (1L) trastuzumab-containing regimens were identified in the English Cancer Outcomes and Services Dataset (Jan 2010–Dec 2019). Tx pathways and outcomes were obtained from the Systemic Anti-Cancer Therapy Dataset, which captured nearly all treatments in England. A novel regimen-based algorithm for reporting Tx sequencing and outcomes was developed since line of therapy was not in the database. Descriptive statistics were reported. Overall survival (OS) and time to Tx discontinuation or death (TTD) underwent Kaplan–Meier analysis.
Results
A total of 948 patients were identified. At the start of their 1L trastuzumab-containing Tx, median age was 67 years (interquartile range [IQR] 57–73]); 82.1% were male; 90.4% were White; 85.4% had an ECOG status of 0–1; 26.0% had liver metastases; 1.0% had brain metastases; and 81.2% had a Charlson Comorbidity Index of 0–1. Three hundred and sixteen patients (33.3%) received 2L onward; 63 (6.6%) received 3L onward. The most common 2L regimens were paclitaxel (n=115 [36.4%]), docetaxel (n=98 [31.0%]), and 5-fluorouracil (5FU) + irinotecan (n=19 [6.0%]). Common 3L regimens included 5FU + irinotecan (n=12 [19.1%]), paclitaxel (n=11 [17.5%]) and capecitabine + irinotecan (n=10 [15.9%]). Median TTD was 2.8 months from the start of 2L. Median OS was 6.1 months (IQR, 3.4–11.2) from the start of 2L and 5.9 months (IQR, 3.2–9.5) from the start of 3L.
Conclusions
Survival of patients with GC/GEJ adenocarcinoma previously treated with 1L anti-HER2 regimens remains poor after 2L and 3L therapy, which is limited mainly to chemotherapy. These findings reflect an urgent need to improve 2L and 3L options.
Clinical trial identification
Editorial acknowledgement
Medical writing and editorial assistance were provided by Julia C. Jones (PharmD, PhD), Erica Cave (PhD), and Daria Renshaw from IQVIA, funded by the study sponsors.
Legal entity responsible for the study
AstraZeneca, Daiichi Sankyo.
Funding
AstraZeneca, Daiichi Sankyo.
Disclosure
N. Starling: Financial Interests, Personal, Advisory Board: GSK, Novartis, MSD Oncology, Servier, AstraZeneca, Pfizer, Gilead Sciences; Financial Interests, Personal, Invited Speaker: Clinical Options, Eli Lilly, Pierre Fabre, Amgen, Merck, Novartis, MSD Oncology, GSK, Servier, Seagen; Financial Interests, Institutional, Research Grant, Sept 2017 (24m) Paid to institution research: Merck; Financial Interests, Institutional, Research Grant, Nov 2017 (48m) -Paid to institution research fund: AstraZeneca; Financial Interests, Institutional, Research Grant, Jan 2018 - Paid to institution research fund: Pfizer; Financial Interests, Institutional, Research Grant, July 2018 (36m) Paid to institution research fund: BMS; Financial Interests, Institutional, Research Grant, June 2022 -: Guardant; Non-Financial Interests, Advisory Role, Ad Board uncompensated.: Guardant. L. Zhang: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Non-Financial Interests, Institutional, Funding, Funding for present abstract: Daiichi Sankyo, AstraZeneca. K. Dunton, A. Struebing, Y. Xiong: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo. C. Livings: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Non-Financial Interests, Institutional, Funding, Funding for present abstract: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. L. Brannman: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Non-Financial Interests, Institutional, Funding, Funding for present abstract: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca, Biodesix, Sonic Healthcare, Medtronic. M. Yakhchi Beykloo, H. Mohamed, N. Trankov, P. Egger: Non-Financial Interests, Institutional, Funding, Funding for present abstract: IQVIA, AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Full or part-time Employment: IQVIA.
Resources from the same session
1665P - Prognostic impact of diabetes and antidiabetic medication in pancreatic cancer patients
Presenter: Alexander Friedrich
Session: Poster session 22
1667P - Clinical and molecular features of young onset pancreatic adenocarcinoma
Presenter: Maxime Remond
Session: Poster session 22
1668P - Prevalence and management of pancreatic ductal adenocarcinoma (PDAC) over a decade in France: A population-based study
Presenter: Léo Mas
Session: Poster session 22
1670P - Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
Presenter: Alejandra Cardozo
Session: Poster session 22
1671P - Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
Presenter: Teresa Macarulla
Session: Poster session 22
1673P - Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study
Presenter: Sofie Olsson Hau
Session: Poster session 22
1674P - VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic
Presenter: Stanislav Batko
Session: Poster session 22
1675P - Diagnostic performance of blood-based DNA methylation assay using epigenetic-specific peptide nucleic acid in pancreatic adenocarcinoma
Presenter: Hongsik Kim
Session: Poster session 22
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22